We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$664M
AUM Growth
+$213M
Cap. Flow
+$183M
Cap. Flow %
27.49%
Top 10 Hldgs %
99.99%
Holding
12
New
2
Increased
7
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$46.6M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$29.1M
3
MDCO
Medicines Co
MDCO
+$20.2M
4
BIIB icon
Biogen
BIIB
+$19.8M
5
MRSN
Mersana Therapeutics
MRSN
+$18.9M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$174K

Sector Composition

Rank Sector Weight
1 Healthcare 84.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$127M 19.13%
868,000
+321,500
+59% +$46.6M
BIIB icon
2
Biogen
BIIB
$30B
$124M 18.67%
524,658
+62,800
+14% +$19.8M
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$102M 15.36%
9,005,387
+1,540,141
+21% +$17.2M
MDCO
4
DELISTED
Medicines Co
MDCO
$102M 15.3%
3,636,000
+855,000
+31% +$20.2M
INVA icon
5
Innoviva
INVA
$1.55B
$84.5M 12.73%
6,026,100
+975,000
+19% +$15.8M
PBYI icon
6
Puma Biotechnology
PBYI
$404M
$55M 8.27%
1,417,000
+74,000
+6% +$2.26M
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$35.8M 5.39%
320,000
+266,000
+493% +$29.1M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$19.7M 2.97%
+150,000
New +$18.9M
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.9B
$14.3M 2.15%
+100,000
New +$13M
ABBV icon
10
AbbVie
ABBV
$443B
$80K 0.01%
1,000
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$73K 0.01%
1,000
– –
SHPG
12
DELISTED
Shire pic
SHPG
– –
-1,000
Closed -$174K

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sarissa Capital Management held 12 positions worth $664M, up 47% from $451M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $183M of net new capital in Q1 2019, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was Mersana Therapeutics: 150,000 shares worth $19.7M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier.

On the sell side, the most notable exit was Shire pic, an estimated $174K sold.

  • Sarissa Capital Management's largest Q1 2019 buy was Mersana Therapeutics: 150,000 shares worth $19.7M.
  • Sarissa Capital Management added most to Allergan plc in Q1 2019, an estimated $46.6M increase.
  • Sarissa Capital Management fully exited Shire pic in Q1 2019, selling an estimated $174K.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $664M portfolio in Q1 2019.
  • Sarissa Capital Management opened 2 new positions and closed 1 in Q1 2019.
  • Sarissa Capital Management's portfolio value rose 47% quarter-over-quarter to $664M.

Based on Sarissa Capital Management's 13F filing for Q1 2019, filed 15 May 2019.